Equities research analysts expect Homology Medicines, Inc. (NASDAQ:FIXX) to announce ($0.58) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Homology Medicines’ earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.67). Homology Medicines posted earnings of ($0.62) per share in the same quarter last year, which would suggest a positive year over year growth rate of 6.5%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 10th.
According to Zacks, analysts expect that Homology Medicines will report full-year earnings of ($1.72) per share for the current financial year, with EPS estimates ranging from ($1.80) to ($1.60). For the next financial year, analysts forecast that the company will report earnings of ($2.39) per share, with EPS estimates ranging from ($2.85) to ($1.91). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Homology Medicines.
Homology Medicines (NASDAQ:FIXX) last issued its quarterly earnings results on Monday, November 15th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.06. The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $0.63 million. Homology Medicines had a negative return on equity of 44.87% and a negative net margin of 269.33%.
FIXX traded up $0.04 during trading on Friday, hitting $3.69. 327,113 shares of the stock were exchanged, compared to its average volume of 386,395. The firm has a 50 day simple moving average of $4.57 and a 200 day simple moving average of $6.07. The firm has a market cap of $210.88 million, a price-to-earnings ratio of -2.15 and a beta of -0.60. Homology Medicines has a 1 year low of $3.37 and a 1 year high of $15.24.
A number of hedge funds and other institutional investors have recently made changes to their positions in FIXX. Macquarie Group Ltd. boosted its position in shares of Homology Medicines by 732.7% in the 2nd quarter. Macquarie Group Ltd. now owns 6,012 shares of the company’s stock worth $44,000 after purchasing an additional 5,290 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Homology Medicines by 30.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 7,850 shares of the company’s stock worth $57,000 after purchasing an additional 1,850 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Homology Medicines by 78.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,863 shares of the company’s stock worth $57,000 after purchasing an additional 3,461 shares in the last quarter. Citigroup Inc. boosted its position in shares of Homology Medicines by 26.0% in the 3rd quarter. Citigroup Inc. now owns 8,362 shares of the company’s stock worth $66,000 after purchasing an additional 1,724 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new stake in shares of Homology Medicines in the 2nd quarter worth $68,000. 55.66% of the stock is currently owned by institutional investors and hedge funds.
Homology Medicines Company Profile
Homology Medicines, Inc is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing, and gene therapy technologies into novel treatments for patients with rare diseases.
Featured Story: Growth and Income Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.